- RecruitingPHASE2, PHASE3
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
This study is looking into a new medicine called efgartigimod for young people aged 12 to 17 with a blood condition called chronic ITP. The aim is to find the best dose to help increase their platelet count and manage their condition.
For: Immune Thrombocytopenia (ITP) · ITP - Immune Thrombocytopenia · ITPGermany · Italy · Poland - Active not recruitingPHASE3
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
This study is testing a new medicine called efgartigimod for people with a type of Myasthenia Gravis (MG). It checks how well it works and if it's safe compared to a dummy medicine. Some people will then get the new medicine openly.
For: Generalized Myasthenia Gravis · gMG · Myasthenia Gravis, GeneralizedUnited States · Belgium · Canada - RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
This study is testing a new medicine called efgartigimod for adults with a blood condition called primary immune thrombocytopenia (ITP). Researchers want to see if it's safe and helps increase blood platelet counts. Some people will get the study drug, others a placebo (dummy drug).
For: Primary Immune Thrombocytopenia (ITP)United States · Austria · Bulgaria - RecruitingPHASE2, PHASE3
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
This study is looking at a new treatment called efgartigimod for children and teenagers aged 2 to 18 with a muscle condition called generalized myasthenia gravis (gMG). It will examine how the treatment works in the body and its safety.
For: Generalized Myasthenia GravisUnited States · Austria · Belgium